FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Psychopharmacologic Drugs Panel Renewal

[ Price : $8.95]

Federal Register notice: FDA renews its Psychopharmacologic Drugs Advisory Committee for an additional two years beyond the charte...

FDA Explains New LabelComp Tool

[ Price : $8.95]

FDA says its new LabelComp artificial intelligence tool automates the identification of adverse event changes in drug labeling upd...

FDA OKs Expanded Jemperli Indication

[ Price : $8.95]

FDA approves an sBLA expanding the endometrial cancer indication for GlaxoSmithKlines Jemperli.

Abbott Device Correction on FreeStyle Libre 3

[ Price : $8.95]

Abbott issues a medical device correction for a small number of FreeStyle Libre 3 sensors because they may provide incorrect high ...

Novartis Sues FDA to Reverse Generic Entresto OK

[ Price : $8.95]

Novartis files a lawsuit against FDA that seeks to reverse the agencys recent approval of MSN Laboratories generic version of Nova...

Telix Pharma Hit with Refuse-to-File on BLA

[ Price : $8.95]

FDA sends Telix Pharmaceuticals a refuse-to-file letter on its BLA for TLX250-CDx (89Zr-DFO-girentuximab), an investigational imag...

Stakeholder Comments on Cell, Gene Guidance

[ Price : $8.95]

Three stakeholders recommend changes to an FDA draft guidance on human- and animal-derived materials in cell and gene therapeutic ...

FDA Publishes ICH Bioequivalence Guidance

[ Price : $8.95]

FDA publishes an International Council on Harmonization guidance on bioequivalence studies for immediate-release solid oral dosage...

FDA Clears Life Spine Sacroiliac Fixation Device

[ Price : $8.95]

FDA clears a Life Spine 510(k) for its ARx SAI (sacral alar iliac) Spinal Fixation System.

FDA May Allow Novel Carve-Ins: Attorneys

[ Price : $8.95]

Two Axinn attorneys say FDA may be signaling more flexibility in considering novel Section viii carve-in statements in ANDAs.